Beta Bionics (NASDAQ:BBNX) Trading Up 13.7% – Time to Buy?

Posted by Brenda Bartman on Aug 9th, 2026

Beta Bionics, Inc. (NASDAQ:BBNX – Get Free Report)’s share price was up 13.7% during mid-day trading on Friday . The company traded as high as $15.84 and last traded at $16.0450. 649,324 shares changed hands during trading, a decline of 44% from the average daily volume of 1,156,924 shares. The stock had previously closed at $14.11.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. UBS Group started coverage on shares of Beta Bionics in a research note on Tuesday, July 28th. They issued a “buy” rating and a $22.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Beta Bionics in a research note on Friday, July 17th. Leerink Partners reduced their price target on shares of Beta Bionics from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Wednesday, April 22nd. The Goldman Sachs Group lifted their price target on shares of Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Bank of America dropped their price objective on shares of Beta Bionics from $23.00 to $11.00 and set a “neutral” rating on the stock in a report on Monday, May 18th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Beta Bionics presently has an average rating of “Moderate Buy” and a consensus price target of $20.10.

View Our Latest Stock Analysis on Beta Bionics

Beta Bionics Stock Up 12.7%

The stock has a market cap of $715.34 million, a price-to-earnings ratio of -9.64 and a beta of 3.13. The stock has a 50 day simple moving average of $15.24 and a 200 day simple moving average of $13.10.

Beta Bionics (NASDAQ:BBNX – Get Free Report) last issued its earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The company had revenue of $32.01 million for the quarter. Equities analysts expect that Beta Bionics, Inc. will post -2.1 earnings per share for the current year.

Insider Buying and Selling at Beta Bionics

In other news, insider Steven Jon Russell sold 4,222 shares of Beta Bionics stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total transaction of $53,239.42. Following the completion of the transaction, the insider directly owned 173,849 shares in the company, valued at $2,192,235.89. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Mark Hopman sold 5,329 shares of the business’s stock in a transaction dated Tuesday, June 2nd. The stock was sold at an average price of $12.61, for a total transaction of $67,198.69. Following the sale, the insider directly owned 130,887 shares of the company’s stock, valued at approximately $1,650,485.07. The trade was a 3.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 40,351 shares of company stock worth $553,961 in the last ninety days. 5.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Beta Bionics

Several large investors have recently added to or reduced their stakes in BBNX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Beta Bionics during the 1st quarter valued at about $95,000. Goldman Sachs Group Inc. purchased a new stake in shares of Beta Bionics in the first quarter worth approximately $715,000. Woodline Partners LP bought a new position in shares of Beta Bionics in the first quarter valued at approximately $1,530,000. Strs Ohio bought a new position in shares of Beta Bionics in the first quarter valued at approximately $29,000. Finally, Rhumbline Advisers bought a new position in shares of Beta Bionics in the first quarter valued at approximately $158,000.

Beta Bionics Company Profile

(Get Free Report)

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.